Find your next paid study

Digestive Care, Inc.NCT07335523

~$10 – $1,050

Malignancy, HematologicNeoplasms, HematologicNeoplasms, Hematopoietic+8 more

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the …

National Cancer Institute (NCI)NCT06904066

~$10 – $5,625

NHLBI-Emory Advanced Cardiac CT Reconstruction

Background: Doctors use computed tomography (CT) to get detailed pictures of the heart. CT uses x-rays to gather raw data. Computers assemble this data to mak…

Structural Heart Disease

National Heart, Lung, and Blood Institute (NHLBI)NCT05372627

~$10 – $675

Causal Mechanisms of Odor-Guided Behavior in Humans

Background: Little is known about how different regions of the brain responsible for the human sense of smell guide behaviors. In this study, researchers use …

Normal Physiology

National Institute on Drug Abuse (NIDA)NCT07099092

~$10 – $5,625

Phase 4

A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Four-Way Crossover Study Evaluating the Abuse Potential of Two Doses of Gabapentin Taken Orally in Healthy, Non-Drug-Dependent Participants With Sedative Drug Use Experience

The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent …

Healthy Non-dependent, Recreational Sedative Users

Viatris Inc.NCT07777965

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to…

Episodic Migraine

Merz Therapeutics GmbHNCT07018700

A Phase 1, Randomized, Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of Influenza A Group 1 and Influenza A Group 2 mRNA Chimeric Hemagglutinin Vaccine Candidates Alone and in Combination in Healthy Adults.

This is a Phase 1, randomized, controlled, dose-ranging clinical trial to assess the safety and immunogenicity of novel influenza A Group 1 and influenza A Gro…

Influenza

National Institute of Allergy and Infectious Diseases (NIAID)NCT07703514

~$10 – $5,625

Phase 2

Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplima…

Head and Neck Squamous Cell Carcinoma (HNSCC)

Regeneron PharmaceuticalsNCT06769698

Phase 2

NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma

Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vo…

Neuroblastoma

New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241

~$10 – $7,500

Ovarian CancerLung AdenocarcinomaEndometrial Cancer+1 more

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is saf…

Triple-Negative Breast Cancer

~$10 – $7,500

AstraZenecaNCT05797168

Phase 3

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compar…

Merck Sharp & Dohme LLCNCT06393374

Phase 2

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplat…

Urothelial CancerBladder Cancer